A U.S. District Judge has ruled that Dexcom Inc. infringed on a patent related to glucose monitoring technology, owned by a unit of Abbott Laboratories. The decision comes in the wake of a Delaware federal jury’s inability to reach a verdict on the matter earlier this year. This legal development marks a significant point in the ongoing intellectual property dispute between the two companies.
While the details of the court’s ruling are not extensively covered in public reports, the implications for both the medical device and corporate sectors could be considerable, particularly in the competitive field of diabetes management technology.
For further details on the proceedings and implications of this ruling, visit Law360’s report on the case.